-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is the second most common hematological malignancy
Multiple myeloma (MM) is the second most common hematological malignancy
EMD is divided into primary EMD (detected when MM is diagnosed) and secondary EMD (detected when MM relapses), and the prognosis of secondary EMD is poor
They analyzed 234 patients with secondary EMD among 4,985 MM patients diagnosed in the Czech Republic from 2005 to 2017 to clarify the risk factors for the development of secondary EMD
Figure 1: Clinical characteristics of patients with multiple myeloma (MM) and secondary extramedullary multiple myeloma (EMD) measured at the time of diagnosis
Figure 1: Clinical characteristics of patients with multiple myeloma (MM) and secondary extramedullary multiple myeloma (EMD) measured at the time of diagnosis
They found that younger age [<65 years; odds ratio (OR) 4.
Figure 2: The impact of future development of secondary extramedullary multiple myeloma (EMD) on progression-free (PFS) and overall (OS) survival rates in different treatment lines
Figure 2: The impact of future development of secondary extramedullary multiple myeloma (EMD) on progression-free (PFS) and overall (OS) survival rates in different treatment lines
Compared with NDMM patients without future EMD, newly diagnosed MM (NDMM) patients with subsequent EMD have a lower median progression-free (PFS) and overall (OS) survival rate [mPFS: 13.
In general, they found that MM patients with future EMD development showed specific characteristics (younger age, extensive bone disease, IgA or nonsecretory MM) that were already present at the time of MM diagnosis
Original source:
Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, Brozova L, Jarkovsky J, Spicka I, Straub J, Pavlicek P, Jungova A, Jelinek T, Sandecka V, Maisnar V, Hajek R, Pour L Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Leave a message here
